Janux Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Eric Dobmeier

Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Eric Dobmeier”): 46,279,387 for, 1,090,512 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignat…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 11,531,316 for, 530,281 withheld, 3 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Natasha Hernday

Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Natasha Hernday”): 42,850,103 for, 4,519,796 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignat…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 11,475,835 for, 585,757 withheld, 8 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Janux Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 42,749,182 for, 4,574,376 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 11,236,189 for, 810,786 against, 14,574 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 176 managers: 34,091,187 for, 3,849,921 against, 151,532 abstained, 4,097 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Janux Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 53,560,969 for, 113,446 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 12,047,026 for, 14,574 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.